Intellia rises after enrolling patients in late-stage trial of genetic disorder drug
ReutersSep 18, 2025 12:13 PM
Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 5.3% to $13.07 premarket
Company says it has completed enrolling patients in a late-stage study of its experimental therapy, lonvoguran ziclumeran (lonvo-z), for the treatment of hereditary angioedema
Hereditary Angioedema is characterized by severe, recurring, and unpredictable swelling attacks in parts of the body including the skin, gastrointestinal tract, and airways
Company expects late-stage study data in H1 2026
Intellia says it is on track to submit a biologics license application in H2 2026 to support the company's plans for a potential U.S. launch in H1 2027
As of last close, stock up 6.4% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).TradingKey
17 hours ago
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
